Connor, Clark & Lunn Investment Management (CC&L)’s Theravance Biopharma TBPH Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $624K | Buy |
+56,613
| New | +$624K | ﹤0.01% | 1191 |
|
|
2024
Q3 | – | Sell |
-16,023
| Closed | -$136K | – | 1635 |
|
|
2024
Q2 | $136K | Buy |
+16,023
| New | +$136K | ﹤0.01% | 1291 |
|
|
2022
Q2 | – | Sell |
-40,477
| Closed | -$387K | – | 1194 |
|
|
2022
Q1 | $387K | Buy |
40,477
+7,443
| +23% | +$71.2K | ﹤0.01% | 829 |
|
|
2021
Q4 | $365K | Sell |
33,034
-11,203
| -25% | -$124K | ﹤0.01% | 863 |
|
|
2021
Q3 | $327K | Buy |
+44,237
| New | +$327K | ﹤0.01% | 853 |
|